Plain-English translation of NCT03971487 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
Researchers believe that some cases of psychosis diagnosed as schizophrenia may actually be caused by the immune system attacking the brain by mistake — similar to 'friendly fire.' This trial tests whether ocrelizumab, a medication that suppresses this harmful immune attack, can reduce psychotic symptoms in young adults who fit this profile. Half of participants will receive the medication, and half will receive a placebo (a dummy treatment) so researchers can fairly compare how well it works.
Doctors don't yet know whether some people diagnosed with schizophrenia actually have this autoimmune problem instead. If they do, this medication might help them in a completely different way than standard antipsychotic drugs. This trial aims to find out whether the treatment works for this specific group of patients.
You likely qualify if…
You likely don't qualify if…
You will receive two intravenous infusions (medicine through an IV) given two weeks apart. You'll be randomly assigned to receive either the experimental medication or a placebo that looks identical. Throughout the study, you'll complete visits where doctors assess your symptoms using standard psychiatric rating scales. The trial will track whether your symptoms improve, stay the same, or worsen compared to the placebo group.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
United States